IL6 activates STAT3
severe acute respiratory syndrome coronavirus 2 activates COVID-19
STAT3 activates IL6
NFkappaB activates IL6
cytokine activates STAT3
IL6ST activates STAT3
STAT3 activates NFkappaB
ACE2 inhibits inflammatory response
Severe Acute Respiratory Syndrome activates Severe Acute Respiratory Syndrome
AGT activates ADAM17
Syndrome activates Severe Acute Respiratory Syndrome
ARDS activates Death
RENBP activates COVID-19
Infections activates NFkappaB
Infections activates STAT3
Sepsis activates Syndrome
camostat activates severe acute respiratory syndrome coronavirus 2
Pneumonia activates Syndrome
ACE2 inhibits ARDS
severe acute respiratory syndrome coronavirus 2 activates NFkappaB
IL6 activates severe acute respiratory syndrome coronavirus 2
IL6 activates Autoimmune Diseases
acute respiratory syndrome coronavirus SARS-CoV respiratory syndrome coronavirus MERS-CoV were transmitted animals humans activates respiratory diseases SARS
AngII-AT1R activates ADAM17
AngII-AT1R activates disintegrin
AngII-AT1R activates metalloprotease 17
proinflammatory cytokines inhibits host
RENBP activates IL-6 Amp
severe acute respiratory syndrome coronavirus 2 inhibits cell entry
TMPRSS2 activates cell entry
accumulated AngII activates inflammatory cytokines including TNFalpha IL-6-soluble s IL-6R
ACE2 activates SARS-2-S protein
ACE2-mediated inhibits angiotensin
AGT activates IL-6-soluble (s)IL-6R
AGT activates metalloprotease 17
alveola cells express ACE2 TMPRSS2 steady activates cells be primary entry cells SARS-CoV-2 lung
ammonium chloride inhibits ACE2
ammonium chloride inhibits SARS-2-S-driven entry 293T cells TMPRSS2-negative expressing ACE2
AngII-AT1R activates NFkappaB
AngII-AT1R axis activates NF-kappaB disintegrin metalloprotease ADAM17
angiotensin receptor activates SARS-CoV-induced ARDS animal model
antigen binding activates SARS-2-S-driven entry human cell lines
antigen binding inhibits SARS-S
camostat mesylate inhibits SARS-2-S-driven entry Caco-2 cells
camostat mesylate inhibits SARS-2-S-driven entry lung cells
camostat mesylate E-64d inhibits entry
CatB/L inhibits ACE2
chronic inflammation induced latter phase activates ARDS-mediated death
chronic inflammation induced latter phase is main cause ARDS-mediated death activates therapeutic targets
Eguchi activates mature epidermal growth receptor EGFR ligands TNFalpha
hyper-activation transcription NF-kappaB activates cytokine-related syndrome
IL-6 Amp activates Autoimmune Diseases
IL-6 Amp activates Chemokine
IL-6 Amp activates severe acute respiratory syndrome coronavirus 2
IL-6 is functional marker cellular senescence activates age-dependent correspond age-dependent COVID-19 mortality
lung inflammation inhibits renin-angiotensin pathway followed development
members IL-6 family cytokines activates STAT3
models inhibits ARDS development
molecule activates indicate possible therapeutic targets COVID-19
NFkappaB activates mature epidermal growth receptor EGFR ligands TNFalpha
NF-kappaB disintegrin metalloprotease ADAM17 activates mature epidermal growth receptor EGFR ligands TNFalpha
pathogenic SARS-coronavirus activates COVID-19
potential AngII-AT1R pathway ACE2 inhibits cytokine release syndrome
proven TMPRSS2 activates SARS-2-S-driven entry Caco-2 cells
recombinant ACE2 inhibits ARDS development
SARS-CoV-2 infection respiratory system activates NFkappaB
SARS-CoV-2 infection respiratory system activates STAT3
TWIST1 activates found chimeric antigen receptor